{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:34:35Z","timestamp":1790890475640,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"University of Colorado Health"},{"name":"Allergen USA, Inc."},{"name":"Melinta Therapeutics, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Long-acting lipoglycopeptides (laLGPs) are FDA approved only for acute bacterial skin and skin structure infections (ABSSSIs). However, these antibiotics show promise for off-label use, reductions in hospital length of stay (LOS) and healthcare cost savings.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To assess the effectiveness, safety, impact on LOS and estimated cost savings from laLGP treatment for Gram-positive infections.<\/jats:p><\/jats:sec>Methods<\/jats:title>Retrospective cohort of adult patients who received at least one dose of laLGPs at the University of Colorado Health system. Descriptive statistics were utilized for analysis.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 59 patients screened, 56 were included: mean age 47\u2009years, 59% male and 30% injection drug users\/polysubstance abusers (dalbavancin, 71%; oritavancin, 25%; both, 4%). Most common indications for laLGP: ABSSSIs (36%), osteomyelitis (27%) and endocarditis (9%). Most common isolated pathogens: MSSA and MRSA (25% and 19%, respectively), Enterococcus faecalis (11%) and CoNS (11%). Previous antibiotics were administered for a median of 13\u2009days (IQR\u205f=\u205f7.0\u201324.5\u2009days) and laLGPs for a median of one dose (IQR\u205f=\u205f1\u20132 doses). Ten (18%) patients were lost to follow-up. Clinical failure was found in 7\/47 (15%) cases with adequate follow-up. Mild adverse effects occurred in six (11%) patients. Projected reduction in hospital LOS and health-system costs were 514\u2009days (9.18\u2009days\/person average) and $963456.72 ($17204.58\/person average), respectively.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Prospective trials are needed to validate the use of these antibiotics for Gram-positive infections in practice, with the hope that they will reduce hospital LOS and the need for daily antibiotic infusions to provide alternative options for patients not qualifying for outpatient parenteral antimicrobial therapy.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkz162","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T20:32:07Z","timestamp":1553632327000},"page":"2405-2416","source":"Crossref","is-referenced-by-count":89,"title":["On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections"],"prefix":"10.1093","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-043X","authenticated-orcid":false,"given":"Taylor","family":"Morrisette","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"},{"name":"Department of Pharmacy-Infectious Diseases, University of Colorado Hospital, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Infectious Diseases, University of Colorado Hospital, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T","family":"Montague","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA"},{"name":"Department of Medicine, University of Colorado Hospital, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard R","family":"Barber","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Infectious Diseases, University of Colorado Hospital, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Brett","family":"McQueen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Outcomes Research, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1746-7462","authenticated-orcid":false,"given":"Martin","family":"Krsak","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA"},{"name":"Department of Medicine, University of Colorado Hospital, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"2019091012085355500_dkz162-B1"},{"key":"2019091012085355500_dkz162-B2","year":"2014"},{"key":"2019091012085355500_dkz162-B3","year":"2014"},{"key":"2019091012085355500_dkz162-B4","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1093\/jac\/dky235","article-title":"Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16","volume":"73","author":"Pfaller","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019091012085355500_dkz162-B5","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1128\/AAC.00952-09","article-title":"Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates","volume":"53","author":"Arhin","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085355500_dkz162-B6","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"2019091012085355500_dkz162-B7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of Gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B8","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"2019091012085355500_dkz162-B9","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/508456","article-title":"Experience of infectious diseases consultants with outpatient parenteral antimicrobial therapy: results of an emerging infections network survey","volume":"43","author":"Chary","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B11","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B12","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2019091012085355500_dkz162-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B14","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jac\/dkp377","article-title":"Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?","volume":"65","author":"Nguyen","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2019091012085355500_dkz162-B16","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/cid\/civ750","article-title":"What Medicare is missing","volume":"61","author":"Keller","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B17","doi-asserted-by":"crossref","first-page":"ofx102","DOI":"10.1093\/ofid\/ofx102","article-title":"Risk factors associated with outpatient parenteral antibiotic therapy program failure among intravenous drug users","volume":"4","author":"Buehrle","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2019091012085355500_dkz162-B18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-world experience with oritavancin therapy in invasive Gram-positive infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2019091012085355500_dkz162-B19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections","volume":"38","author":"Schulz","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2019091012085355500_dkz162-B20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different Gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2019091012085355500_dkz162-B21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B22","doi-asserted-by":"crossref","first-page":"19.","DOI":"10.1186\/s12941-015-0081-5","article-title":"Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies","volume":"14","author":"Dunne","year":"2015","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2019091012085355500_dkz162-B23","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1128\/AAC.05098-14","article-title":"Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide","volume":"59","author":"Jones","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085355500_dkz162-B24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3111\/13696998.2015.1078339","article-title":"Assessing the economic value of avoiding hospital admissions by shifting the management of Gram-positive acute bacterial skin and skin-structure infections to an outpatient care setting","volume":"18","author":"Ektare","year":"2015","journal-title":"J Med Econ"},{"key":"2019091012085355500_dkz162-B25","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085355500_dkz162-B26","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2019091012085355500_dkz162-B27","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2019091012085355500_dkz162-B29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jac\/dkm210","article-title":"Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years","volume":"60","author":"Matthews","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2019091012085355500_dkz162-B30","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the clinical use of vancomycin","volume":"60","author":"\u00c1lvarez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085355500_dkz162-B31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/2042018816638223","article-title":"Review of vancomycin-induced renal toxicity: an update","volume":"7","author":"Bamgbola","year":"2016","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2019091012085355500_dkz162-B32","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1086\/533592","article-title":"Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus","volume":"46","author":"Sakoulas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1469-0691.2006.01344.x","article-title":"The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus","volume":"12","author":"Appelbaum","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"2019091012085355500_dkz162-B34","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","article-title":"Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus","volume":"50","author":"Cui","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085355500_dkz162-B35","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.50.4.1581-1585.2006","article-title":"Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin","volume":"50","author":"Sakoulas","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012085355500_dkz162-B36","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy1134","article-title":"Short course antibiotic therapy\u2014replacing Constantine units with \u201cshorter is better\u201d","author":"Wald-Dickler","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B37","doi-asserted-by":"crossref","first-page":"ofy132","DOI":"10.1093\/ofid\/ofy132","article-title":"Infectious diseases physicians\u2019 perspectives regarding injection drug use and related infections, United States, 2017","volume":"5","author":"Rapoport","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2019091012085355500_dkz162-B38","doi-asserted-by":"crossref","first-page":"43.","DOI":"10.1186\/1472-6963-5-43","article-title":"Willingness to pay to assess patient preferences for therapy in a Canadian setting","volume":"5","author":"Marra","year":"2005","journal-title":"BMC Health Serv Res"},{"key":"2019091012085355500_dkz162-B39","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.cmi.2017.07.028","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2019091012085355500_dkz162-B40","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1093\/ofid\/ofx163.800","article-title":"A little bit of dalba goes a long way: dalbavancin use in a vulnerable patient population","volume":"4","author":"Bryson-Cahn","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2019091012085355500_dkz162-B41","doi-asserted-by":"crossref","first-page":"ofy026","DOI":"10.1093\/ofid\/ofy026","article-title":"Infectious diseases consultation reduces 30-day and 1-year all-cause mortality for multidrug-resistant organism infections","volume":"5","author":"Burnham","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2019091012085355500_dkz162-B42","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/cid\/civ120","article-title":"Impact of infectious disease consultation on quality of care, mortality, and length of stay in Staphylococcus aureus bacteremia: results from a large multicenter cohort study","volume":"60","author":"Bai","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019091012085355500_dkz162-B43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cmi.2014.07.006","article-title":"Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation","volume":"21","author":"Farmakiotis","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2019091012085355500_dkz162-B44","first-page":"558","article-title":"Impact of infectious diseases consultation on mortality of Cryptococcal infection in patients without HIV","volume":"64","author":"Spec","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz162\/28505964\/dkz162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/8\/2405\/28963383\/dkz162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T23:39:03Z","timestamp":1607038743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/8\/2405\/5477400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,4,23]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz162","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,4,23]]}}}